Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Three projects from MSD were amongst 10 from across the University to receive funding from the second round of the Public Engagement with Research Seed Fund.

Dr Marco J. Haenssgen, based in the Centre for Tropical Medicine & Global Health, part of the Nuffield Department of Medicine, received funding  to evaluate the process and impact of health-themed science theatre as part of ongoing public engagement activities at the Mahidol Oxford Tropical Medicine Research Unit (MORU). In order to engage the public with its research, MORU is collaborating with B-floor Theatre to produce a performance entitled Fishy Clouds, which explores antimicrobial resistance through puppet plays for both children and adults in Thailand. The social outcomes of drama performances are difficult to evaluate and little guidance exists in the evaluation research literature. This project will test out methods for evaluation, and in doing so inform the theory and practice of evaluating such engagement activities for others.

Simon Knight, based at the Oxford Transplant Centre, part of the Nuffield Department of Surgical Sciences, was awarded funding to develop an online patient advisory panel for renal and transplant research in Oxford, which will provide a patient perspective on upcoming research projects and patient materials.

Dr Marta Valente Pinto, part of the Department of Paediatrics, where she studies pertussis diseases / whooping cough, a highly contagious respiratory infection that, although to some extent preventable by vaccines, continues to be a significant burden around the world. Her project will involve the creation and delivery of workshops in Thames Valley Primary and Secondary Schools to help children and parents understand more about the disease, and to make more informed decisions about vaccinations and to stimulated their interest and involvement in research.

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.